Hutchmed's li­cens­ing deal, worth up to $227M; Tyra's $200 PIPE

Plus, news about An­bo­gen Ther­a­peu­tics and Ve­ra Ther­a­peu­tics:

Hutchmed inks deal of up to $227.5M: The com­pa­ny is li­cens­ing two drugs to Im­ma­gene Bio­phar­ma­ceu­ti­cals: IMG-007, which is be­ing test­ed as a treat­ment for atopic der­mati­tis and alope­cia area­ta, and IMG-004, an oral BTK in­hibitor that tar­gets im­muno­log­i­cal dis­eases. Hutchmed could re­ceive up to $92.5 mil­lion in de­vel­op­ment mile­stones and up to $135 mil­lion in com­mer­cial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER